636 BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials

MLA

Marcela Maus, et al. “636 BASECAMP-1: A Master Prescreening Study to Identify Patients with High-Risk or Metastatic Solid Tumors with HLA Loss of Heterozygosity (LOH) in Preparation for Tmod CAR T-Cell Therapy Trials.” Journal for ImmunoTherapy of Cancer, vol. 11, no. Suppl 1, Nov. 2023. EBSCOhost, https://doi.org/10.1136/jitc-2023-SITC2023.0636.

APA

Marcela Maus, Caron Jacobson, Frederick L Locke, Oliver Dorigo, David Maloney, Jennifer Specht, Saurabh Dahiya, Edward Garon, Diane M Simeone, John Welch, Kedar Kirtane, Marwan Fakih, Julian Molina, Ariane Lozac’hmeur, J Randolph Hecht, Jong Chul Park, Caleb Smith, Theodore Welling, M Pia Morelli, … Gayanie Ong. (2023). 636 BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials. Journal for ImmunoTherapy of Cancer, 11(Suppl 1). https://doi.org/10.1136/jitc-2023-SITC2023.0636

Chicago

Marcela Maus, Caron Jacobson, Frederick L Locke, Oliver Dorigo, David Maloney, Jennifer Specht, Saurabh Dahiya, et al. 2023. “636 BASECAMP-1: A Master Prescreening Study to Identify Patients with High-Risk or Metastatic Solid Tumors with HLA Loss of Heterozygosity (LOH) in Preparation for Tmod CAR T-Cell Therapy Trials.” Journal for ImmunoTherapy of Cancer 11 (Suppl 1). doi:10.1136/jitc-2023-SITC2023.0636.